organization · Reporting owner

BRISTOL MYERS SQUIBB CO

Disclosed activity across 7 companies

Tapewire entity: 1662
SEC CIK: 0000014272

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IMCOR PHARMACEUTICAL COICPH · Entity 17599	10% owner	October 29, 2004	November 08, 2004
INHIBITEX, INC.INHX · Entity 16805	10% owner	February 13, 2012	February 15, 2012
Kyto Technology & Life Science, Inc.KBPH · Entity 16492	10% owner	March 31, 2010	September 23, 2014
ZYMOGENETICS INCZGEN · Entity 16945	10% owner	October 08, 2010	October 08, 2010

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IMCOR PHARMACEUTICAL CO

Report date October 29, 2004 · Filed November 08, 2004

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Series A Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.27	Direct	Not disclosed	Reported balance Holding disclosure · report date 2004-10-29 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Bristol-Myers Squibb Company (BMS) directly owns 4,500 shares of the Series A Convertible Preferred Stock ("Preferred Stock") reported herein. F5: This initial conversion price is subject to adjustments for dilution resulting from stock splits and combinations, certain dividends and distributions, and the reorganization, reclassification or merger of the Issuer, in each case as set forth in the Certificate of Designation. F2: The Preferred Stock may be converted into the Issuer's Common Stock under the following circumstances: (i) by BMS at any time after July 29, 2005 or (ii) by the Issuer at any time after October 29, 2005 provided that the closing price of the Issuer's Common Stock exceeds the conversion price of $0.27 by 50% for any ten (10) consecutive trading days. F3: Not applicable. F4: Each share of Preferred Stock is convertible into approximately 3,703.7 shares of Common Stock; in the aggregate, the 4,500 shares of Preferred Stock owned by BMS are convertible into approximately 16,666,667 shares of the Issuer's Common Stock.

Filing footnotes · ownership attribution and instrument terms

F1: Bristol-Myers Squibb Company (BMS) directly owns 4,500 shares of the Series A Convertible Preferred Stock ("Preferred Stock") reported herein.

F2: The Preferred Stock may be converted into the Issuer's Common Stock under the following circumstances: (i) by BMS at any time after July 29, 2005 or (ii) by the Issuer at any time after October 29, 2005 provided that the closing price of the Issuer's Common Stock exceeds the conversion price of $0.27 by 50% for any ten (10) consecutive trading days.

F3: Not applicable.

F4: Each share of Preferred Stock is convertible into approximately 3,703.7 shares of Common Stock; in the aggregate, the 4,500 shares of Preferred Stock owned by BMS are convertible into approximately 16,666,667 shares of the Issuer's Common Stock.

F5: This initial conversion price is subject to adjustments for dilution resulting from stock splits and combinations, certain dividends and distributions, and the reorganization, reclassification or merger of the Issuer, in each case as set forth in the Certificate of Designation.

INHIBITEX, INC.

Report date February 13, 2012 · Filed February 15, 2012

Jointly reported with Inta Acquisition Corp

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCK, PAR VALUE $0.001 PER SHARESEC Table I · non-derivative	IndirectSEE NOTES	85,342,020	Reported balance After 2012-02-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2012-02-13 · Other · Acquired 81,793,316 · Balance 85,342,020 F1: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash. F3: At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. F5: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding. F4: Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a "Stockholder"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the "Support Agreement"). Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser. Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser.
COMMON STOCK, PAR VALUE $0.001 PER SHARESEC Table I · non-derivative	IndirectSEE NOTES	85,342,020	Reported balance After 2012-02-13 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2012-02-13 · Other · Acquired 3,548,704 · Balance 85,342,020 F1: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash. F4: Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a "Stockholder"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the "Support Agreement"). Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser. Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser. F5: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding. F3: At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn.

Filing footnotes · ownership attribution and instrument terms

F1: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent").

F2: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash.

F3: At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn.

F4: Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a "Stockholder"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the "Support Agreement"). Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser. Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser.

F5: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding.

Kyto Technology & Life Science, Inc.

Report date March 31, 2010 · Filed September 23, 2014

Jointly reported with MEDAREX INC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Medarex, L.L.C.	1,300,000	Reported balance Holding disclosure · report date 2010-03-31 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,300,000 F1: Bristol-Myers Squibb Company ("BMS") recently identified its indirect ownership of 1,300,000 shares of common stock of Kyto Biopharma, Inc. ("Kyto"). These shares are owned directly by Medarex, L.L.C. (formerly known as Medarex, Inc.) ("Medarex"), a wholly-owned subsidiary of BMS. BMS acquired Medarex on September 1, 2009. At that time, Medarex owned 1,300,000 Kyto shares but only provided BMS with a stock certificate, in the name of Kyto's predecessor company B. Twelve, Inc., for 400,000 shares.

Filing footnotes · ownership attribution and instrument terms

F1: Bristol-Myers Squibb Company ("BMS") recently identified its indirect ownership of 1,300,000 shares of common stock of Kyto Biopharma, Inc. ("Kyto"). These shares are owned directly by Medarex, L.L.C. (formerly known as Medarex, Inc.) ("Medarex"), a wholly-owned subsidiary of BMS. BMS acquired Medarex on September 1, 2009. At that time, Medarex owned 1,300,000 Kyto shares but only provided BMS with a stock certificate, in the name of Kyto's predecessor company B. Twelve, Inc., for 400,000 shares.

ZYMOGENETICS INC

Report date October 08, 2010 · Filed October 08, 2010

Jointly reported with Zeus Acquisition Corp

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee note	82,605,529	Reported balance After 2010-10-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2010-10-08 · Other · Acquired 82,605,529 · Balance 82,605,529 F1: Zeus Acquisition Corporation, a Washington corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2: On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the "Offer") for a purchase price of $9.75 per share in cash (the "Offer Price"). F3: At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding.

Filing footnotes · ownership attribution and instrument terms

F1: Zeus Acquisition Corporation, a Washington corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent").

F2: On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the "Offer") for a purchase price of $9.75 per share in cash (the "Offer Price").

F3: At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACCELERON PHARMA INC

Report date July 09, 2020 · Filed July 13, 2020

Jointly reported with CELGENE CORP /DE/

Section 16 reporting ended · disclosed 2020-07-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,010,751	Reported balance After 2020-07-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-07-09 · Other · Acquired 38,979 · Balance 7,010,751 F1: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons"). F2: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities.
Common StockSEC Table I · non-derivative	Direct	7,008,510	Reported balance After 2020-07-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-07-09 · Sale · Disposed 2,241 · Balance 7,008,510 F3: On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares.
Option WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2020-07-09	Direct	0	Reported balance After 2020-07-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-09 · Other · Disposed 38,979 · Balance 0 F4: All of the shares are currently exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons").

F2: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities.

F3: On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares.

F4: All of the shares are currently exercisable.

ANESIVA, INC.

Report date February 18, 2004 · Filed February 18, 2004

Section 16 reporting ended · disclosed 2004-02-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,079,002	Reported balance After 2004-02-18 transaction · row 1 1 source row Row 1 · 2004-02-18 · Conversion · Acquired 2,079,002 · Balance 2,079,002
Series D Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2004-02-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2004-02-18 · Conversion · Disposed 2,079,002 · Balance 0 F1: The Issuer's preferred stock automatically converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering.

Filing footnotes · ownership attribution and instrument terms

F1: The Issuer's preferred stock automatically converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering.

Mead Johnson Nutrition Co

Report date December 18, 2009 · Filed December 22, 2009

Section 16 reporting ended · disclosed 2009-12-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2009-12-18 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2009-12-18 · Conversion · Acquired 127,655,429 · Balance 170,000,000 F1: The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price. Row 2 · 2009-12-18 · Other · Disposed 170,000,000 · Balance 0 F2: Bristol-Myers Squibb Company ("BMS") disposed of 170,000,000 shares of Class A Common Stock in exchange for 269,285,601 shares of BMS common stock pursuant to a registered exchange offer to BMS common stockholders. The final exchange ratio for the exchange offer was 0.6313 shares of Class A Common Stock per share of BMS common stock accepted in the exchange offer. As a result of the exchange offer, BMS has disposed of its entire equity interest in the Issuer. The closing price of BMS common stock on the New York Stock Exchange on December 18, 2009 was $25.78.
Class B Common StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2009-12-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2009-12-18 · Conversion · Disposed 127,655,429 · Balance 0 F3: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date. F1: The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price. F4: Prior to November 13, 2009, the reported securities were owned directly by E.R. Squibb & Sons, L.L.C. ("ERS"), which is a wholly-owned subsidiary of BMS. On November 13, 2009, ERS distributed the reported securities to BMS.

Filing footnotes · ownership attribution and instrument terms

F1: The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price.

F2: Bristol-Myers Squibb Company ("BMS") disposed of 170,000,000 shares of Class A Common Stock in exchange for 269,285,601 shares of BMS common stock pursuant to a registered exchange offer to BMS common stockholders. The final exchange ratio for the exchange offer was 0.6313 shares of Class A Common Stock per share of BMS common stock accepted in the exchange offer. As a result of the exchange offer, BMS has disposed of its entire equity interest in the Issuer. The closing price of BMS common stock on the New York Stock Exchange on December 18, 2009 was $25.78.

F3: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date.

F4: Prior to November 13, 2009, the reported securities were owned directly by E.R. Squibb & Sons, L.L.C. ("ERS"), which is a wholly-owned subsidiary of BMS. On November 13, 2009, ERS distributed the reported securities to BMS.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 09, 2020 Filed Jul 13, 2020 22:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherOption Warrant · Derivative	38,979	$0.00 Strike: $5.88	$0.00	Disclosure SEC source: 0001104659-20-083172 · tm2024764-1_4.xml · derivative · entry 3 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.001 par value · 38,979 shares Expires 2020-07-09 F4 · derivative.exercise_date: All of the shares are currently exercisable. Read SEC document
July 09, 2020 Filed Jul 13, 2020 22:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	SaleCommon Stock	2,241	$102.28	$229,209.48	Disclosure SEC source: 0001104659-20-083172 · tm2024764-1_4.xml · nonDerivative · entry 2 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,008,510 F3 · kind: On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares. Read SEC document
July 09, 2020 Filed Jul 13, 2020 22:27 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	OtherCommon Stock	38,979	$5.88	$229,196.52	Disclosure SEC source: 0001104659-20-083172 · tm2024764-1_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,010,751 F1 · ownership.direct: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons"). F2 · ownership.direct: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities. Read SEC document
July 01, 2020 Filed Jul 6, 2020 21:24 UTC	ACCELERON PHARMA INC XLRN · Entity 15780	PurchaseCommon Stock	108,108	$92.50	$9,999,990.00	Disclosure SEC source: 0001104659-20-081337 · tm2024196-2_4.xml · nonDerivative · entry 1 CELGENE CORP /DE/ · CIK 0000816284 · 10% owner BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,971,772 F1 · ownership.direct: This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company. F2 · ownership.direct: These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities. Read SEC document
February 13, 2012 Filed Feb 15, 2012 21:36 UTC	INHIBITEX, INC. INHX · Entity 16805	OtherCOMMON STOCK, PAR VALUE $0.001 PER SHARE	3,548,704	$26.00	$92,266,304.00	Disclosure SEC source: 0001181431-12-009127 · rrd334186.xml · nonDerivative · entry 2 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Inta Acquisition Corp · CIK 0001539753 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · SEE NOTES Disclosed balance after: 85,342,020 F1 · shares: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · shares: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash. F4 · shares: Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a "Stockholder"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the "Support Agreement"). Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser. Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser. F5 · shares: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding. F1 · balance_after: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · balance_after: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash. F3 · balance_after: At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. F4 · balance_after: Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a "Stockholder"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the "Support Agreement"). Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser. Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser. F5 · balance_after: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding. F1 · ownership.direct: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). Read SEC document
February 13, 2012 Filed Feb 15, 2012 21:36 UTC	INHIBITEX, INC. INHX · Entity 16805	OtherCOMMON STOCK, PAR VALUE $0.001 PER SHARE	81,793,316	$26.00	$2,126,626,216.00	Disclosure SEC source: 0001181431-12-009127 · rrd334186.xml · nonDerivative · entry 1 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Inta Acquisition Corp · CIK 0001539753 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · SEE NOTES Disclosed balance after: 85,342,020 F1 · shares: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · shares: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash. F3 · shares: At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. F5 · shares: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding. F1 · balance_after: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · balance_after: On January 7, 2012, Inhibitex, Inc. ("Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser commenced a cash tender offer to acquire all of the shares of the Issuer's common stock (the "Offer") for a purchase price of $26.00 per share in cash. F3 · balance_after: At 12:00 midnight, New York City time, on February 10, 2012, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 81,793,316 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 4,260,705 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. F4 · balance_after: Concurrently with the execution of the Merger Agreement, each of Gabriele Cerrone, Panetta Partners, Ltd., Russell H. Plumb, New Enterprise Associates 10, Limited Partnership, New Enterprise Associates 11, Limited Partnership and Michael James Barrett (each, a "Stockholder"), among others, entered into a Tender and Support Agreement with the Issuer, Parent and Purchaser (the "Support Agreement"). Pursuant to the Support Agreement, each Stockholder, among other things, elected to exercise such Stockholder's warrants and/or vested options, on a net exercise basis, following the acceptance of the Offer and to transfer those newly-issued Shares to Purchaser. Collectively, the Stockholders transferred 3,548,704 shares of Common Stock to Purchaser. F5 · balance_after: The shares of Common Stock validly tendered and not validly withdrawn collectively with the shares of Common Stock transferred to Purchaser under the Support Agreement represent approximately 96% of the shares of Common Stock outstanding. F1 · ownership.direct: Inta Acquisition Corporation, a Delaware corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). Read SEC document
October 08, 2010 Filed Oct 8, 2010 21:12 UTC	ZYMOGENETICS INC ZGEN · Entity 16945	OtherCommon Stock	82,605,529	$9.75	$805,403,907.75	Disclosure SEC source: 0001181431-10-050368 · rrd288286.xml · nonDerivative · entry 1 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner Zeus Acquisition Corp · CIK 0001501223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See note Disclosed balance after: 82,605,529 F1 · shares: Zeus Acquisition Corporation, a Washington corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · shares: On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the "Offer") for a purchase price of $9.75 per share in cash (the "Offer Price"). F3 · shares: At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding. F1 · balance_after: Zeus Acquisition Corporation, a Washington corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · balance_after: On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the "Offer") for a purchase price of $9.75 per share in cash (the "Offer Price"). F3 · balance_after: At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding. F1 · ownership.direct: Zeus Acquisition Corporation, a Washington corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · ownership.direct: On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the "Offer") for a purchase price of $9.75 per share in cash (the "Offer Price"). F3 · ownership.direct: At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding. F1 · ownership.nature: Zeus Acquisition Corporation, a Washington corporation ("Purchaser"), is wholly-owned by Bristol-Myers Squibb Company ("Parent"). F2 · ownership.nature: On September 7, 2010, ZymoGenetics, Inc. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Purchaser. Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, Purchaser has commenced a cash tender offer to acquire all of the shares of the Issuer's Common Stock (the "Offer") for a purchase price of $9.75 per share in cash (the "Offer Price"). F3 · ownership.nature: At 12:00 midnight, New York City time, on October 7, 2010, the Offer expired as scheduled. The Offer was not extended. Based on the information provided by the depositary for the Offer to Parent, as of the expiration of the Offer, approximately 82,605,529 shares of Common Stock were validly tendered and not validly withdrawn prior to the expiration of the Offer, including approximately 1,501,981 shares of Common Stock subject to guaranteed delivery procedures. Purchaser has accepted for payment all shares of Common Stock validly tendered and not validly withdrawn. The shares of Common Stock validly tendered and not validly withdrawn represent approximately 94.9% of the shares of Common Stock outstanding. Read SEC document
December 18, 2009 Filed Dec 22, 2009 22:15 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	ConversionClass B Common Stock · Derivative	127,655,429	$0.00	$0.00	Disclosure SEC source: 0001181431-09-058294 · rrd260711.xml · derivative · entry 3 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 127,655,429 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Class B Common Stock was convertible into Class A Common Stock at any time on a one-for-one basis and had no exercise or conversion price or expiration date. F1 · derivative.exercise_date: The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price. F1 · derivative.expiration_date: The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price. F4 · ownership.direct: Prior to November 13, 2009, the reported securities were owned directly by E.R. Squibb & Sons, L.L.C. ("ERS"), which is a wholly-owned subsidiary of BMS. On November 13, 2009, ERS distributed the reported securities to BMS. Read SEC document
December 18, 2009 Filed Dec 22, 2009 22:15 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	OtherClass A Common Stock	170,000,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001181431-09-058294 · rrd260711.xml · nonDerivative · entry 2 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Bristol-Myers Squibb Company ("BMS") disposed of 170,000,000 shares of Class A Common Stock in exchange for 269,285,601 shares of BMS common stock pursuant to a registered exchange offer to BMS common stockholders. The final exchange ratio for the exchange offer was 0.6313 shares of Class A Common Stock per share of BMS common stock accepted in the exchange offer. As a result of the exchange offer, BMS has disposed of its entire equity interest in the Issuer. The closing price of BMS common stock on the New York Stock Exchange on December 18, 2009 was $25.78. Read SEC document
December 18, 2009 Filed Dec 22, 2009 22:15 UTC	Mead Johnson Nutrition Co MJN · Entity 17020	ConversionClass A Common Stock	127,655,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001181431-09-058294 · rrd260711.xml · nonDerivative · entry 1 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Class A Common Stock was acquired pursuant to the conversion of Class B Common Stock in an exempt transaction under Rule 16b-6(b). The Class B Common Stock was converted into Class A Common Stock on a one-for-one basis and had no exercise or conversion price. Read SEC document
February 18, 2004 Filed Feb 18, 2004 23:52 UTC	ANESIVA, INC. CGTK · Entity 13652	ConversionSeries D Preferred Stock · Derivative	2,079,002	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-04-005036 · a4.xml · derivative · entry 2 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · Former 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,079,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: The Issuer's preferred stock automatically converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering. Read SEC document
February 18, 2004 Filed Feb 18, 2004 23:52 UTC	ANESIVA, INC. CGTK · Entity 13652	ConversionCommon Stock	2,079,002	$0.00	$0.00	Disclosure SEC source: 0001104659-04-005036 · a4.xml · nonDerivative · entry 1 BRISTOL MYERS SQUIBB CO · CIK 0000014272 · Former 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,079,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.